|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
80,420,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
76,000 |
76,000 |
1,876,000 |
1,876,000 |
Total Buy Value |
$475,760 |
$475,760 |
$18,475,760 |
$18,475,760 |
Total People Bought |
1 |
1 |
2 |
2 |
Total Buy Transactions |
1 |
1 |
2 |
2 |
Total Shares Sold |
1,514 |
1,514 |
2,068 |
1,570,794 |
Total Sell Value |
$12,475 |
$12,475 |
$18,818 |
$35,262,071 |
Total People Sold |
1 |
1 |
2 |
7 |
Total Sell Transactions |
1 |
1 |
2 |
35 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Alphabet Inc. |
Member of 10% Group |
|
2022-11-01 |
4 |
AS |
$36.69 |
$2,351,706 |
I/I |
(63,926) |
4,386,850 |
|
- |
|
Alphabet Inc. |
Member of 10% Group |
|
2022-11-01 |
4 |
AS |
$0.00 |
$0 |
I/I |
(31,963) |
6,235,245 |
|
- |
|
Yeshwant Krishna |
Director |
|
2022-10-31 |
4 |
AS |
$37.91 |
$2,074,643 |
I/I |
(53,696) |
4,418,813 |
|
- |
|
Yeshwant Krishna |
Director |
|
2022-10-31 |
4 |
AS |
$0.00 |
$0 |
I/I |
(53,697) |
6,267,208 |
|
- |
|
Alphabet Inc. |
Member of 10% Group |
|
2022-10-31 |
4 |
AS |
$37.91 |
$4,149,325 |
I/I |
(107,393) |
4,418,813 |
|
- |
|
Alphabet Inc. |
Member of 10% Group |
|
2022-10-31 |
4 |
AS |
$0.00 |
$0 |
I/I |
(53,697) |
6,267,208 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-10-28 |
4 |
AS |
$39.90 |
$399,000 |
D/D |
(10,000) |
6,629 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-10-28 |
4 |
OE |
$1.48 |
$14,800 |
D/D |
10,000 |
16,629 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-10-03 |
4 |
AS |
$33.02 |
$1,682,622 |
D/D |
(50,000) |
317,839 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-10-03 |
4 |
OE |
$1.39 |
$69,500 |
D/D |
50,000 |
367,839 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-09-23 |
4 |
AS |
$34.67 |
$2,120,392 |
D/D |
(60,000) |
6,629 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-09-23 |
4 |
OE |
$1.48 |
$88,800 |
D/D |
60,000 |
46,629 |
|
- |
|
Ashe Andrew D. |
See Remarks |
|
2022-08-25 |
4 |
OE |
$1.39 |
$152,217 |
D/D |
95,787 |
266,509 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-08-10 |
4 |
AS |
$29.90 |
$1,495,000 |
D/D |
(50,000) |
317,839 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-08-10 |
4 |
OE |
$1.39 |
$69,500 |
D/D |
50,000 |
367,839 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-07-20 |
4 |
AS |
$34.90 |
$698,000 |
D/D |
(20,000) |
6,629 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-07-20 |
4 |
OE |
$1.39 |
$27,800 |
D/D |
20,000 |
26,629 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-07-19 |
4 |
AS |
$29.90 |
$1,495,000 |
D/D |
(50,000) |
317,839 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-07-19 |
4 |
OE |
$1.39 |
$69,500 |
D/D |
50,000 |
367,839 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-07-13 |
4 |
AS |
$24.90 |
$249,000 |
D/D |
(10,000) |
6,629 |
|
- |
|
Bellinger Andrew |
CSO & CMO |
|
2022-07-13 |
4 |
OE |
$1.48 |
$14,800 |
D/D |
10,000 |
16,629 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-07-12 |
4 |
S |
$19.98 |
$3,386,520 |
I/I |
(163,000) |
570,729 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-07-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
160,000 |
240,997 |
|
- |
|
Kathiresan Sekar |
Chief Executive Officer |
|
2022-07-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
160,000 |
317,839 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2022-07-01 |
4 |
S |
$15.66 |
$607,217 |
I/I |
(38,775) |
773,729 |
|
- |
|
99 Records found
|
|
Page 2 of 4 |
|
|